IP Verse

Administration Of Deuterated Cftr Potentiators - EP3352757

The patent EP3352757 was granted to Vertex Pharmaceuticals Europe on Aug 16, 2023. The application was originally filed on Sep 21, 2016 under application number EP16849524A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3352757

VERTEX PHARMACEUTICALS EUROPE
Application Number
EP16849524A
Filing Date
Sep 21, 2016
Status
Granted And Under Opposition
Jul 14, 2023
Grant Date
Aug 16, 2023
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

GENERICS UKMay 16, 2024TER MEER STEINMEISTER & PARTNERADMISSIBLE

Patent Citations (14) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONUS2006079502
DESCRIPTIONUS2006094744
DESCRIPTIONUS7014866
DESCRIPTIONUS8754224
DESCRIPTIONUS8865902
DESCRIPTIONUS8883206
INTERNATIONAL-SEARCH-REPORTUS2014073667
INTERNATIONAL-SEARCH-REPORTUS2014221424
OPPOSITIONUS2015099780
OPPOSITIONWO2010019239
OPPOSITIONWO2011146901
OPPOSITIONWO2017053455
SEARCHUS2011288122
SEARCHUS2015099780

Non-Patent Literature (NPL) Citations (15) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
EXAMINATION- TALAL ANDREW H. ET AL, "Assessment of Hepatic Impairment and Implications for Pharmacokinetics of Substance Use Treatment : Clinical Pharmacology in Drug Development", vol. 6, no. 2, doi:10.1002/cpdd.336, ISSN 2160-763X, (20170301), pages 206 - 212, CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, URL: https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fcpdd.336, XP055790187
EXAMINATION- DIETRICH CHRISTOPH G, "Molecular changes in hepatic metabolism and transport in cirrhosis and their functional importance", WORLD JOURNAL OF GASTROENTEROLOGY, CN, (20160101), vol. 22, no. 1, doi:10.3748/wjg.v22.i1.72, ISSN 1007-9327, page 72, XP055790114
OPPOSITION- Harbeson S, Nguyen, S.; Bridson, G.; Uttamsingh, V.; Wu, L.; Morgan, A.J.; Aslanian, A.; Braman, V.; Pilja, L, "PHARMACOKINETIC STUDIES OF DEUTERATED ANALOGS OF IVACAFTOR IN PRECLINICAL MODELS AND HEALTHY VOLUNTEERS", Pediatric Pulmonology, Poster Session Abstract 29, (20150101), vol. 50, no. S41, page 202, XP093191967-
OPPOSITION- "KALYDECO™ (IVACAFTOR) Tablets", HIGHLIGHTS OF PRESCRIBING INFORMATION, (20120101), pages 1 - 13, XP055577989-
OPPOSITION- Marciel Kristen K., Saiman Lisa, Quittell Lynne M., Dawkins Kevin, Quittner Alexandra L., "Cell phone intervention to improve adherence: Cystic fibrosis care team, patient, and parent perspectives", Author manuscript -Pediatric Pulmonology, (20100201), pages 1 - 13, XP093231083-
OPPOSITION- Nguyen Sophia, Gary Bridson, Adam Morgan, Richard Gallegos, Scott Harbeson, Lijun Wu And Vinita Uttamsingh, "P309. DEUTERATED ISOTOPOLOGS OF IVACAFTOR HAVE IMPROVED METABOLISM AND PHARMACOKINETIC PROPERTIES", Drug Metabolism Reviews, (20130101), vol. 45, no. Suppl. 1, page 188, XP093191957-
OPPOSITION- Partridge Michael, Eric Rojas, Zach Barber, "Vertex to Acquire CTP-656 from Concert Pharmaceuticals for the Treatment of Cystic Fibrosis", Press Release, Vertex Pharmaceuticals Incorporated, (20170306), pages 1 - 3, Press Release, URL: https://investors.vrtx.com/news-releases/news-release-details/vertex-acquire-ctp-656-concert-pharmaceuticals-treatment-cystic, XP093275466-
OPPOSITION- Scott L. Harbeson, Tung, R.D., "Deuterium Medicinal Chemistry: A New Approach to Drug Discovery and Development", MedChem News, (20140501), vol. 24, no. 2, pages 8 - 22, XP055246294-
OPPOSITION- Talal Andrew H., Venuto Charles S., Younis Islam, "Assessment of Hepatic Impairment and Implications for Pharmacokinetics of Substance Use Treatment", Author manuscript - Clinical Pharmacology in Drug Development, (20170301), pages 1 - 12, XP093231075-
OPPOSITION- Robert Tardif, Jules Brodeur, "Pharmacokinetics/Toxicokinetics", Robert Tardif, Jules Brodeur, Philip Wexler, Encyclopedia of Toxicology (Second Edition), Elsevier, (20050602), pages 383 - 390, doi:10.1016/B0-12-369400-0/00746-8, ISBN 0-12-745353-9, XP009561054
OPPOSITION- Cai, Z., Scott-Ward, T.S., Li, H. , Schmidt, A. , Sheppard, D.N., "Strategies to investigate the mechanism of action of CFTR modulators", Journal of Cystic Fibrosis, NL , (20040801), vol. 3, doi:10.1016/j.jcf.2004.05.030, ISSN 1569-1993, pages 141 - 147, XP004556448
OPPOSITION- Martinez Fernando J., Criner Gerard J., Gessner Christian, Jandl Margret, Scherbovsky Fernando, Shinkai Masaharu, Siler Thomas M., Vogelmeier Claus F., Voves Robert, Wedzicha Jadwiga A., Bartels Christian, Bottoli Ivan, Byiers Stuart, Cardenas Pamela, Eckert Joerg H., Gutzwiller Florian S., Knorr Barbara, Kothari Mahavir, Parlikar Rutvick, Tanase Ana-Maria, Franssen Frits M.E., "Icenticaftor, a CFTR Potentiator, in COPD: A Multicenter, Parallel-Group, Double-Blind Clinical Trial", American Thoracic Society 2020 International Conference; May 15-20, 2020, American Thoracic Society, (20230815), vol. 208, no. 4, doi:10.1164/rccm.202303-0458OC, ISSN 1073-449X, pages 417 - 427, XP093191956
OPPOSITION- Martignoni Marcella, Groothuis Geny M M, De Kanter Ruben, "Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction", Expert Opinion on Drug Metabolism & Toxicology, Ashley Productions London, GB, GB , (20061201), vol. 2, no. 6, doi:10.1517/17425255.2.6.875, ISSN 1742-5255, pages 875 - 894, XP093208054
OPPOSITION- Dietrich Christoph G , Oliver Götze, Andreas Geier, "Molecular changes in hepatic metabolism and transport in cirrhosis and their functional importance", World Journal of Gastroenterology, CN , (20160101), vol. 22, no. 1, doi:10.3748/wjg.v22.i1.72, ISSN 1007-9327, pages 72 - 88, XP055790114
SEARCH- UTTAMSINEH V ET AL, "WS13.6 CTP-656 tablet confirmed superiority of pharmacokinetic profile relative to Kalydeco in Phase I clinical studies", JOURNAL OF CYSTIC FIBROSIS, (20160601), vol. 15, doi:10.1016/S1569-1993(16)30138-2, ISSN 1569-1993, XP029572015 [PX] 1-5,7-8,10-11,13 * Abstract WS13.6 * [I] 3,6,9,12

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents